David A. Siegel Avidity Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 249,400 shares of RNA stock, worth $10.6 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
249,400
Previous 453,900
45.05%
Holding current value
$10.6 Million
Previous $11.6 Million
12.05%
% of portfolio
0.02%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding RNA
# of Institutions
206Shares Held
95.5MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$462 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$373 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$365 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$275 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$252 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.21B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...